Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing

References

• Medical products for rare diseases and conditions [internet]. Silver Spring (MD): Food and Drug Administration; 2022 May 12 [cited 2023 Dec 18]. Available from: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
   Google Scholar
• Orphan incentives [Internet]. Amsterdam: European Medicines Agency;no date [cited 2023 Dec 18]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives
   Google Scholar
• Orphan drug designation [Internet]. Woden (ACT): Australian Government; 2018 Aug [cited 2023 Dec 18]. Available from: https://www.tga.gov.au/sites/default/files/orphan-drug-designation.pdf
   Google Scholar
• Government of Canada improves access to affordable and effective drugs for rare diseases [internet]. Ottawa (ON): Government of Canada; 2023 Mar 22 [cited 2023 Dec 18]. Available from: https://www.canada.ca/en/health-canada/news/2023/03/government-of-canada-improves-access-to-affordable-and-effective-drugs-for-rare-diseases.html
   Google Scholar
• Impact of PMPRB pricing changes: final research report [Internet]. Toronto (ON): Research Etc; 2020 Feb 2 [cited 2023 Dec 18]. Available from: https://lifesciencesontario.ca/wp-content/uploads/2020/02/Research-Etc.-PMPRB-Survey-02-03-20.pdf
   Google Scholar
• Rawson NSB. Canada falls behind in new drug submissions compared with the United States and Europe [internet]. Can Health Policy J. Toronto (ON): Canadian Health Policy Institute. 2023 [cited 2023 Dec 18]. Available from:2023(JAN):1–11. doi: 10.54194/HKBH7107
   Google Scholar
• What we do [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar 3 [cited 2023 Dec 18]. Available from: https://www.cadth.ca/what-we-do
   Google Scholar
• Notice of Compliance search [Internet]. Ottawa (ON): Government of Canada, 2022 Nov 25 [cited 2023 Dec 18]. Available from: https://health-products.canada.ca/noc-ac/?lang=eng
   Google Scholar
• Reimbursement review reports [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Dec 18 [cited 2023 Dec 18]. Available from: https://www.cadth.ca/reimbursement-review-reports
   Google Scholar
• Brand name drug negotiations status [Internet]. Toronto (ON): pan-Canadian Pharmaceutical Alliance; 2023 [cited 2023 Dec 18]. Available from: https://www.pcpacanada.ca/negotiations
   Google Scholar
• BC PharmaCare formulary search [Internet]. Victoria (BC): Government of British Columbia; 2023 Dec 5 [cited 2023 Dec 18]. Available from: https://pharmacareformularysearch.gov.bc.ca/Search.xhtml
   Google Scholar
• Welcome to the iDBL [internet]. Edmonton (AB): Government of Alberta; 2023 Dec 18 [cited 2023 Dec 18]. Available from: https://idbl.ab.bluecross.ca/idbl/load.do
   Google Scholar
• Home – search formulary [internet]. Regina (SK): Government of Saskatchewan; 2023 [cited 2023 Dec 18]. Available from: https://formulary.drugplan.ehealthsask.ca/SearchFormulary
   Google Scholar
• Drug formulary lookup [Internet]. Winnipeg (MB): Manitoba Health; 2023 Dec 18 [cited 2023 Dec 18]. Available from: https://web22.gov.mb.ca/eFormulary/
   Google Scholar
• Formulary search [Internet]. Toronto (ON): Government of Ontario; 2023 Jul 31 [cited 2023 Dec 18]. Available from: https://www.formulary.health.gov.on.ca/formulary/
   Google Scholar
• List of medications [Internet]. Québec (QC): Gouvernement de Québec; 2023 Sep 25 [cited 2023 Dec 18]. Available from: https://www.ramq.gouv.qc.ca/sites/default/files/documents/non_indexes/liste-med-2023-09-27-en.pdf
   Google Scholar
• New Brunswick drug plan formulary [Internet]. Fredericton (NB): Government of New Brunswick; 2023 Dec [cited 2023 Dec 18]. Available from: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf
   Google Scholar
• Formulary [Internet]. Halifax (NS): Government of Nova Scotia; 2023 Dec [cited 2023 Dec 18]. Available from: https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf
   Google Scholar
• PEI Pharmacare formulary [Internet]. Charlottetown (PE): Health PEI; 2023 Dec [cited 2023 Dec 18]. Available from: https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf
   Google Scholar
• Newfoundland and Labrador interchangeable drug products formulary [internet]. St. John’s (NL): Government of Newfoundland and Labrador; 2023 Oct 1 [cited 2023 Dec 18]. Available from: https://www.gov.nl.ca/hcs/files/nlpdp-formularyvol89.pdf
   Google Scholar
• BC Cancer benefit drug list [Internet]. Vancouver (BC): BC Cancer Agency; 2023 Dec [cited 2023 Dec 18]. Available from: http://www.bccancer.bc.ca/systemic-therapy-site/Documents/Policy%20and%20Forms/Benefit%20Drug%20List.pdf
   Google Scholar
• Outpatient cancer drug benefit program [Internet]. Edmonton (AB): Alberta Health Services; 2023 Nov 23 [cited 2023 Dec 18]. Available from: https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf
   Google Scholar
• Saskatchewan Cancer Agency drug formulary [Internet]. Regina (SK): Saskatchewan Cancer Agency; 2023 Sep 1 [cited 2023 Dec 18]. Available from: http://www.saskcancer.ca/images/pdfs/health_professionals/drug_formulary/drug_formulary/SCA_Drug_Formulary_-_2023-09-01.pdf
   Google Scholar
• Drug formulary [Internet]. Toronto (ON): Cancer Care Ontario; no date [cited 2023 Dec 18]. Available from: https://www.cancercareontario.ca/en/drugformulary/drugs
   Google Scholar
• New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products [internet]. Silver Spring (MD): Food and Drug Administration; 2023 May 22 [cited 2023 Dec 18]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products
   Google Scholar
• Biological approvals by year [internet]. Silver Spring (MD): Food and Drug Administration; 2023 Jul 3 [cited 2023 Dec 18]. Available from: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year
   Google Scholar
• Drugs@FDA: FDA-approved drugs [Internet]. Silver Spring (MD):Food and Drug Administration; no date [cited 2023 Dec 18]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   Google Scholar
• Human regulatory: marketing authorization [Internet]. Amsterdam: European Medicines Agency; no date [cited 2023 Dec 18]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation
   Google Scholar
• Drug products: what information can you find here? [internet]. Ottawa (ON): Government of Canada; 2023 Jun 23 [cited 2023 Dec 18]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/drug-products.html
   Google Scholar
• Technology appraisal guidance [Internet]. London: National Institute for Health and Care Excellence; 2023 [cited 2023 Dec 18]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
   Google Scholar
• Guidance, NICE standards and quality standards [Internet]. London: National Institute for Health and Care Excellence; 2023 [cited 2023 Dec 18]. Available from: https://www.nice.org.uk/guidance/published?ndt=Guidance&ndt=Quality%20standard
   Google Scholar
• Rawson NSB. Canadian, European and United States new drug approval times now relatively similar. Regul Toxicol Pharmacol. 2018;96:121–126 doi: 10.1016/j.yrtph.2018.05.002
   PubMed Web of Science ®Google Scholar
• Oppenheimer J, Hoyte FCL, Phipatanakul W, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129(2):169–80. doi: 10.1016/j.anai.2022.02.021
   PubMed Web of Science ®Google Scholar
• Rodak O, Peris-Diaz MD, Olbromski M, et al. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers (Basel). 2021;13(18):4705. doi: 10.3390/cancers13184705
   PubMed Web of Science ®Google Scholar
• Lexchin J. Time to potential listing of new drugs on public and private formularies in Canada: a cross-sectional study. CMAJ Open. 2022;10(4):E993–9. doi: 10.9778/cmajo.20220063
   PubMedGoogle Scholar
• Procedures for CADTH reimbursement reviews [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov [cited 2023 Dec 18]. Available from: https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH%20Drug%20Reimbursement%20Review%20Procedures.pdf
   Google Scholar
• Norton M, Stoddart K, Travaglio M, et al. EFPIA patients WAIT indicator 2022 survey [internet]. IQVIA, 2023 Apr [cited 2023 Dec 18]. Available from: https://www.efpia.eu/media/s4qf1eqo/efpia_patient_wait_indicator_final_report.pdf
   Google Scholar
• Salek S, Lussier Hoskyn S, Johns JR, et al. Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans. Front Pharmacol. 2019;10:196. doi: 10.3389/fphar.2019.00196.
   PubMed Web of Science ®Google Scholar
• Barua B, Westcott W, Vo VN Timely access to new pharmaceuticals in Canada, the United States and the European Union [Internet]. Vancouver (BC): Fraser Institute, 2021 [cited 2023 Dec 18]. Available from: https://www.fraserinstitute.org/sites/default/files/timely-access-to-new-pharmaceuticals-in-canada-US-and-EU.pdf
   Google Scholar
• Ward LM, Chambers A, Mechichi E, et al. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. Orphanet J Rare Dis. 2022;17(1):113. doi: 10.1186/s13023-022-02260-6
   PubMed Web of Science ®Google Scholar
• Skinner B Patent term erosion and the availability of new medicines in Canada, 2000-2022 [internet]. Can Health Policy J. Toronto (ON): Canadian Health Policy Institute; 2022 [cited 2023 Dec 18]. Available from: https://www.canadianhealthpolicy.com/product/patent-term-erosion-and-the-availability-of-new-medicines-in-canada-2000-2022/
   Google Scholar
• Rawson NSB. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: does it lead to improved patient access? J Popul Ther Clin Pharmacol. 2020;27(1):e48–64. doi: 10.15586/jptcp.v27i1.658
   PubMed Web of Science ®Google Scholar
• Rawson NSB. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: who benefits? Orphanet J Rare Dis. 2022;17(1):218. doi: 10.1186/s13023-022-02390-x
   PubMed Web of Science ®Google Scholar
• Fontrier AM, Kanavos P. Do reimbursement recommendations by the Canadian Agency for Drugs and Technologies in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario? Value Health. 2023;26(7):1011–1021.
   PubMed Web of Science ®Google Scholar
• Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res. 2017;9:721–730.
   PubMed Web of Science ®Google Scholar
• Ontario public drug plans [Internet]. Toronto (ON): Office of the Auditor General of Ontario; no date [cited 2023 Dec 18]. Available from: https://www.auditor.on.ca/en/content/annualreports/arreports/en17/v1_309en17.pdf
   Google Scholar
• CADTH partners with international health technology assessment bodies to boost collaboration on shared challenges [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep 6 [cited 2023 Dec 18]. Available from: https://www.cadth.ca/news/cadth-partners-international-health-technology-assessment-bodies-boost-collaboration-shared
   Google Scholar
• Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [Internet]. London: National Institute for Health and Care Excellence; 2021 Aug 25 [cited 2023 Dec 18]. Available from: https://www.nice.org.uk/guidance/ta722/resources/pemigatinib-for-treating-relapsed-or-refractory-advanced-cholangiocarcinoma-with-fgfr2-fusion-or-rearrangement-pdf-82611190679749
   Google Scholar
• CADTH reimbursement recommendation: pemigatinib (Pemazyre) [Internet]. Can J Health Technol. 2022;2(6). [cited 2023 Dec 18]. doi: 10.51731/cjht.2022.358
   Google Scholar
• Stories from the frontlines of the fight for access to innovative therapies [internet]. Toronto (ON): Maclean’s; 2023 Aug 3 [cited 2023 Dec 18]. Available from: https://macleans.ca/longforms/the-fight-for-access-to-innovative-therapies/
   Google Scholar
• Gadaleta-Caldarola G, Rizzo A, Dadduzio V, et al. Pemigatinib in intrahepatic cholangiocarcinoma: a work in progress. Curr Oncol. 2022;29(10):7925–31. doi: 10.3390/curroncol29100626
   PubMed Web of Science ®Google Scholar
• Tam VC, Ramjeesingh R, Burkes R, et al. Emerging systemic therapies in advanced unresectable biliary tract cancer: review and Canadian perspectives. Curr Oncol. 2022;29(10):7072–85. doi: 10.3390/curroncol29100555
   PubMed Web of Science ®Google Scholar
• Exceptional funding of EDRDs [internet]. Victoria (BC): Government of British Columbia; 2023 Jun 22 [cited 2023 Dec 18]. Available from: https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/exceptional-funding-edrd?keyword=case&keyword=by&keyword=case&keyword=rare&keyword=disease&keyword=drugs
   Google Scholar
• Exception drug status [Internet]. Winnipeg (MB): Manitoba Health; 2023 Oct 26 [cited 2023 Dec 18]. Available from: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf
   Google Scholar
• Exceptional access program reimbursement criteria for frequently requested drugs [internet]. Toronto (ON): Ministry of Health; 2023 Aug 8 [cited 2023 Dec 18]. Available from: https://files.ontario.ca/moh-frequently-requested-drugs.pdf
   Google Scholar
• Criteria for the coverage of special authorization drugs [internet]. St. John’s (NL): Government of Newfoundland and Labrador; no date [cited 2023 Dec 18]. Available from: https://www.gov.nl.ca/hcs/files/prescription-special-auth-drug-products.pdf
   Google Scholar
• Begovic M Getting sick to get better: cystic fibrosis patients worry about access to ‘breakthrough’ drug [internet]. Toronto (ON): Healthing.ca; 2022 Oct 5 [cited 2023 Dec 18]. Available from: https://www.healthing.ca/diseases-and-conditions/cystic-fibrosis/trikafta-cystic-fibrosis-drug-access
   Google Scholar
• Abunassar C, Dowson JP, Fleming M, et al. Biopharmaceutical ecosystem index: where does Canada rank on its attractiveness for new medicine launch? [Internet]. Mississauga (ON): PDCI Market Access, 2022 [cited 2023 Dec 18]. Available from: https://www.pdci.ca/wp-content/uploads/2023/05/PDCI-Biopharmaceutical-Ecosystem-Index-May-2023.pdf
   Google Scholar
• Rawson N, Adams J Waiting for new drugs for rare disorders in Canada [Internet]. Ottawa (ON): Macdonald-Laurier Institute, 2023 [cited 2023 Dec 18]. Available from: https://macdonaldlaurier.ca/category/projects/rare-disorder-drugs/
   Google Scholar
• Owens RC Defending our rights: eliminating dysfunction in Canada’s intellectual property regime [internet]. Ottawa (ON): Macdonald-Laurier Institute, 2017 [cited 2023 Dec 18]. Available from: https://macdonaldlaurier.ca/mli-files/pdf/MLI_IPPaper3_06-17_webready.pdf
   Google Scholar
• Now is the time: a strategy for rare diseases is a strategy for all Canadians [internet]. Toronto (ON): Canadian Organization for Rare Disorders; 2015 May [cited 2023 Dec 18]. Available from: https://www.raredisorders.ca/content/uploads/CORD_Canada_RD_Strategy_22May15.pdf
   Google Scholar
• Developing a truly Canadian approach to improving the lives of Canadians with rare diseases [internet]. Toronto (ON): Canadian Organization for Rare Disorders; 2022 Jul 8 [cited 2023 Dec 18]. Available from: http://www.raredisorders.ca/content/uploads/CORD-letter-to-Premiers_08July2022.pdf
   Google Scholar
• Grubert N Innovative access arrangements and managed entry: what Canada can learn from Europe [internet]. Ottawa (ON): Innovative Medicines Canada; no date [cited 2023 Dec 18]. Available from: https://innovativemedicines.ca/wp-content/uploads/2023/04/6328_IMC_ME_IAA_Report_v6.pdf
   Google Scholar
• Lamoreaux K, Lefebvre S, Levine DS, et al. The power of being counted [internet]. Washington (DC): Rare-X, 2022 [cited 2023 Dec 18]. Available from: https://rare-x.org/wp-content/uploads/2022/05/be-counted-052722-WEB.pdf
   Google Scholar
• Djordjevic D, McFadyen A, Anderson JA. Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. J Med Access. 2023;7:27550834231177507. doi: 10.1177/27550834231177507
   Google Scholar